Member Info for Laura2022

This was from circular

Some objectives ( China patent) already met

The Haleon Licence Agreement requires Haleon to pay US$2.5m upon the grant of a US patent for Eroxon that meets the definition of a valid patent claim under the Haleon Licence Agreement. External legal advice received by the Company indicates a high probability of the patent being granted sufficient to trigger the milestone, with payment from Haleon expected to be received in H1 2026.

2026 objectives

The Company is working towards and hoping to achieve the following objectives during 2026:

§

In relation to Eroxon:

o  China patent to be granted

o  US patent milestone payment to be received from Haleon

o  Appointment of APAC partner

§

In relation to Intense:

o  HUT results received supporting commercial decision to launch

o  FDA and EU approval

§

In relation to WSD4000:

o  EFS results received supporting favourable Phase 3 clinical trial design and further insights into product efficacy

o  HUT 1 results with the potential to support a Phase 3 trial and potential launch decision

o  Phase 3 first patient visit

o  HUT 2 results received supporting commercial potential

o  USA, APAC, EMEA and LATAM partner appointments

SETS algorithms often take FUM up 30-40% at a time historically

Fallen from 10p to 1p ( with good reason) but now new funding , direction amd CEO

Options priced at4p +

Hub

Are there some trades yet to appear plz ?

Anyone think its worth looking at CLON or do they yet more funding ?

Spodumene up $72 to $1320 . That means it’s up 100% in last few months .

Justa

Thanksnfor that

Broken 1.2p

For me

FUM PYC 2 of best bio techs from these levels

From the £3mln placing and open offer

The new management incentive plan will have specific performance targets for vesting which are related to the delivery of multiples of the Issue Price. To achieve full vesting a multiple of 4x from the Issue Price is required.

2p at least judging by the new re-build plan/CEO and chart wise

Good morning Rick

Also, after weeks of being 1p to 1.15p it seems like the brwak out is just beginning on the 3mth chart

Hubstar

Yes, while EU/USA been slow thus far

The far East could lead to huge rises (pardon the euphemism)

Wel done for trying

If it helps , R Griffiths has previous form in this situation, including 2 just in the last 3mths

Worth researching him

Annual UK medicines and pharmaceutical exports to South Korea (to mid-2025) were £319m. This is 7% of the UK’s overall goods exports total. 

News announced today of the extended free trade deal between the Uk and South Korea could be of great importance to Futura Medical,the company have patent filings in the country .Pharmaceutical products are explicitly listed among the sectors that benefit from continued preferential treatment, meaning lower or zero tariffs on trade in those goods under the agreement’s goods provisions.

Every morning it opens in auction at1.55p ask for somw reaspm too

Thanks Juxta

Yes, been a £100k buy orde for a week now

Clearly won't get filled

Only 225k shares available.?

Rick/Juxt

Because its SETS traded FUM often motors really quickly once algorithm takes charge

I spoke to the company yesterday and was happy with the responses to various questions

The ceo decision was purely private/individual reasons and decision to stay till June 2026 was clearly a sensible thing to do while new CEO is appointed.

Market cap just £900k.

Key growth in all areas , particularly bio statistics, company very pleased and very confident about the niche growth markets many of which are now mandatory under EU law and most could well become mandatory for drug design. Positive regulatory environment eg FDA

[ ] Key market drivers

* model informed discovery/bio stats help

> costs $2.5bln and 10-15yrs to get drug to market and less than 5% success rate - PYC modelling drastically cuts this and using MMID/BS can

1) save $100-500mln

2) increase to 20-30% success at Phase II

3) 30-50% fewer patients

[ ] Key growth/CAGR markets which PYC operate

MMID 18% CAGR with market set to be $13bln

Bio Statistics 24% CAGR $40bln market

Regulatory authorities across the world require robust biometrics practices to approve new drugs. Biometrics typically incorporates three main areas:

1. Biostatistics: Supporting the design of clinical studies and analysis of resulting data

2. Statistical Programming: Use of programming language to process, analyse and visualise clinical data

3. Data Management: Setup and oversight of the collection, entry, and validation of clinical trial data

Personalised medicine 7.5% CAGR and largest market is North America ( partner DoseMeRx based there)

M

General overviews

Costs at just 3% therefore tracking or below inflation in 2025 so very tight cost mgmt

Total Income at 3yr high and bolstered by moving into new therapeutic areas such as immunology and cardiovascular

Just after year end received £250,000 + and will recieve £60k grant, therefore cash position as of July was almost £800,000

Have applied for other grants and will announce if/when progressed

Conversion rate 2022-2024 was 27%

Conversation rate 2025 jumped to 45%

6 late stage contracts due ( some of which announced Dec 2025)

The "right team" now finally assembled in all key growth areas

Youz

Wondered who it was

Totally agree

Sushi posting history across AIM says it all

Breakout here

1.2p should lead quickly to 1.8p

Buy order of £100k not filled , the grey trade monday was a roll over